Tag: Intermittent claudication
UK MHRA update: Paclitaxel-coated device increased mortality risk is withdrawn for...
Following a review, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has updated guidance on the use of paclitaxel-coated devices stating that such...
Vascular News’ top 10 most popular stories of February 2023
February's top 10 includes the announcement that Abbott is to acquire Cardiovascular Systems, results of the PRESERVE study on the safety and effectiveness of...
Stenting of the SFA for intermittent claudication yields quality-of-life benefits out...
In a recent study of patients with intermittent claudication (IC) caused by isolated superficial femoral artery (SFA) lesions, researchers found that primary stenting conferred...
Patients with claudication receive more “aggressive” surgical management in high-competition regions,...
Demonstrating the “susceptibility” of care delivery to regional market competition, M Libby Weaver (University of Virginia, Charlottesville, USA) presented the case that intermittent claudication...
Female sex is associated with additional treatments following surgical therapies for...
A new US study has found that female sex is associated with more reinterventions after surgical treatment for intermittent claudication. Additionally, guideline-directed medical therapy,...
Study demonstrates feasibility, effectiveness of at-home exercise therapy plus cognitive behaviour...
A mobile phone-administered, home-based exercise therapy programme for patients with intermittent claudication (IC) incorporating cognitive behaviour therapy (CBT) was found to be feasible, with...
